RDEB is a rare inherited skin disorder characterized by extreme skin fragility, chronic wounds, and significant physical and emotional burdens for patients and their families. ZEVASKYN is the first approved therapy of its kind, using a patient’s own genetically modified skin cells to create cellular sheets that can be applied to affected areas.

According to Abeona Therapeutics, the addition of Cincinnati Children’s expands patient access to the treatment through its growing network of specialized care centers. The hospital is recognized as one of the largest epidermolysis bullosa (EB) treatment centers in the United States and has extensive experience caring for individuals affected by RDEB.

Clinicians at Cincinnati Children’s noted that patients with RDEB face substantial daily challenges due to the severity of the condition. The availability of ZEVASKYN provides a new therapeutic option for individuals seeking treatments that may improve wound management and overall quality of life. The institution’s multidisciplinary EB team has a long history of caring for this patient population and will now be able to offer the newly available gene-modified cellular therapy.

Patients and caregivers interested in receiving ZEVASKYN at Cincinnati Children’s can contact the hospital’s EB Center for additional information and treatment eligibility guidance.

Abeona also highlighted support services available through its Abeona Assist® program, which helps patients navigate insurance coverage, financial assistance opportunities, travel arrangements, and other logistical needs associated with treatment access.

The activation of Cincinnati Children’s marks another step in the expansion of specialized treatment infrastructure for RDEB, increasing access to an innovative therapy for patients living with this debilitating genetic disease.